✦ LIBER ✦

Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer

✍ Scribed by M. Ivergård; O. Ström; F. Borgström; R.T. Burge; A.N.A. Tosteson; J. Kanis

Book ID: 116323593
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 625 KB
Volume: 47
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2010.07.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIH11 IDENTIFYING COST-EFFECTIVE TREATME

PIH11 IDENTIFYING COST-EFFECTIVE TREATMENT WITH RALOXIFENE IN POSTMENOPAUSAL WOMEN USING RISK ALGORITHMS FOR FRACTURES AND INVASIVE BREAST CANCER

✍ Ivergard, M; Strom, O; Borgstrom, F; Burge, RT; Tosteson, A; Kanis, JA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Effect of Raloxifene on the Incidence of

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women With Osteoporosis Categorized by Breast Cancer Risk

✍ Beattie, M.S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Cost-effectiveness of raloxifene and hor

Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk

✍ Katrina Armstrong; Tze-Ming Chen; Daniel Albert; Thomas C Randall; J Sanford Sch 📂 Article 📅 2001 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 95 KB

Relative risk for fractures in postmenop

Relative risk for fractures in postmenopausal women, postmenopausal breast cancer survivors and postmenopausal women managed with adjuvant hormonal therapy

✍ R. Bell; Sambrook; Z. Chen; J. Lewis 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Cost-Effectiveness of Using Clinical Ris

Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women

✍ Dirk Mueller; Afschin Gandjour 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB